NG v Chinese Medicine Board of Australia [2017] NSWCATOD 36

Decision date: 15 March 2017
“PROFESSIONS AND TRADES – Where health practitioner has appealed against conditions placed on her registration – where the Chinese Medical Board concedes an error in imposing conditions and has caused removal of conditions from the Register maintained by the Australian Health Practitioner Regulation Agency –
Whether appeal is frivolous or vexatious or misconceived or lacking in substance – Consideration of objects of Civil and Administrative Tribunal Act 2013 (NSW) and of the Health Practitioner Regulation National Law – whether dismissal of appeal would deny appellant procedural fairness. Where continuation of appeal will not result in a practical outcome.”
Find case here.

EU recommends suspending hundreds of drugs tested by Indian firm

Reuters, 25 March 2017
Author: Ben Hirschler
“Europe’s medicines regulator has recommended the suspension of more than 300 generic drug approvals and drug applications due to “unreliable” tests conducted by Indian contract research firm Micro Therapeutic Research Labs.”
Find article here.

Nursing and Midwifery Board of Australia v Brewer (Review and Regulation) [2017] VCAT 384

Date of order: 17 March 2017
“Health Practitioner Regulation National Law (Victoria) Act 2009 – ss 5 & 196 – whether convictions in the Magistrates’ Court, in part concerning theft of medications, stalking, intentionally damaging property, aggravated cruelty to animals, burglary, possessing a drug of dependence, reckless conduct endangering serious injury, recklessly causing serious injury, false imprisonment and intentionally causing serious injury amount to professional misconduct within the National Law – appropriate determinations.”
Find case here.

Prescription Drug Regulation, Promotion, And Advocacy Has Gotten More Vexing In 2017

Health Affairs Blog, 23 March 2017
Author: Jerry Avorn
“Early 2017 has been one of the most interesting and challenging times for anyone concerned with medication regulation and evidence-based prescribing — as well as for the patients and health care professionals who will be so heavily impacted recent policy changes.”
Find article here.

Strong regulation is healthy for complementary medicines

SMH, 21 March 2017
Author: Editorial
“The vitamin and supplement giant Swisse has asked to be liberated from federal government oversight of its advertising claims. When promoting its products, it wants to be spared the scrutiny of the Therapeutic Goods Administration and be subject instead to an industry-funded self-regulation system administered by the Advertising Standards Bureau.”
Find article here.

Scope of practice largely undefined

MJA Insight, 20 March 2017
Author: Sue Ieraci
“Most people working in medicine are familiar with the term “scope of practice”, but many of us may not have thought much about how guidelines are developed or regulated. As more intra- and inter-professional problems occur, however, we may find that the structures for doing so are not as robust as we may hope.”
Find article here.

Pelvic mesh devices hit by allegations of research fraud, experimental surgery on thousands of women

SMH, 14 March 2017
Author: Joanne McCarthy
“Pelvic devices developed in Australia from the 1980s and 1990s are at the centre of a global medical scandal that includes regulatory failure, and allegations of research fraud and experimental surgery on women in multiple countries.”
Find article here.

States Wrestle With Legalizing Payments For Gestational Surrogates

NPR, 10 March 2017
Author: Emily Sohn
“Last month, state legislators proposed a bill that would regulate gestational surrogacy — potentially adding legal oversight to fertility clinics that facilitate these pregnancies, when one woman carries a pregnancy for another. Minnesota’s surrogacy legislation and the debates that surround it echo the larger national debate on reproductive rights.”
Find article here.

(Re)disclosing physician financial interests: rebuilding trust or making unreasonable burdens on physicians?

Med Health Care and Philos (2017).
Author: Daniel Sperling
“Recent professional guidelines published by the General Medical Council instruct physicians in the UK to be honest and open in any financial agreements they have with their patients and third parties. These guidelines are in addition to a European policy addressing disclosure of physician financial interests in the industry. Similarly, In the US, a national open payments program as well as Federal regulations under the Affordable Care Act re-address the issue of disclosure of physician financial interests in America. These new professional and legal changes make us rethink the fiduciary duties of providers working under new organizational and financial schemes, specifically their clinical fidelity and their moral and professional obligations to act in the best interests of patients.”
Find article here.

UK pharma firms accused of illegal deals to hike price of life-saving drug

The Guardian, 3 March 2017
Author: Angela Monaghan
“Two drugs firms have been accused by the competition watchdog of making illegal deals in order to inflate the price for life-saving hydrocortisone tablets in the UK. It is alleged that Actavis UK incentivised its rival Concordia not to enter the market with its own version of the tablets so that it could remain the sole supplier of the drug in the UK and charge higher prices.”
Find article here.